Unveiling the importance of polymorphism in drug development: Insights from Ardena
Ardena shares the latest insights on the critical role of polymorphism in drug development. Learn why early-stage polymorph screens are essential, how they mitigate risks, and the innovative methods Ardena employs to ensure robust drug development.
FETCH wins Venture Challenge Spring 2024
The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2024 spring edition is FETCH!
EMFC sponsor Radboud Summer School course at Pivot Park
Next week it’s that time again: the Radboud Summer School descends on Pivot Park. For 5 days, participants will be immersed in the world of preclinical drug discovery. The fact that this course is a success is evidenced by the EFMC sponsoring it starting this year.
Press release: Strategic partnership BioConnection and AGC Biologics
BioConnection and AGC Biologics partner to offer new end-to-end biopharmaceutical drug substance and drug product development and manufacturing offering.
Cell4Pharma and InnoSer forge partnership to drive integrated preclinical drug screening
Cell4Pharma and InnoSer are proud to announce a strategic partnership aimed at offering integrated preclinical drug screening services.
Minister of Health, Pia Dijkstra, visited Pivot Park
On 15 May 2024, we had the pleasure of a visit from our Minister of Health, Pia Dijkstra. We provided insights into our operations, and afterwards, we discussed strategies for tackling and preventing medicine shortages in the future.
Pivot Park Screening Centre unveils new insulin-regulated aminopeptidase inhibitors
Pivot Park Screening Centre unveils the discovery of new inhibitors of insulin-regulated aminopeptidase by a high-throughput screening of 400,000 drug-like compounds.
Pharming is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact
Awards on 8 June 2024.
Press release: Ardena’s Nanomedicines Facility Marks €20 Million Expansion with first GMP approval
Ardena has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
Flindr Therapeutics B.V. announces a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for treatment of cancer.
Unveiling Pivot Park’s new Business Hub
Discover Pivot Park’s new Business Hub, uniting 14 companies in the campus center. Empowering biopharmaceutical startups and scale-ups for collaborative innovation in pioneering R&D. Join us at the forefront of advancing medicine.
Introducing the Pedro Hermkens Stipend: Empowering professional growth at Pivot Park
At Pivot Park, we recognize the importance of investing in the ongoing development of our community members. The Pedro Hermkens Stipend offers our community a maximum award of 1,000 euros, providing vital support for their career endeavours.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
